Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Epirus Biopharmaceuticals Inc EPRSQ

Healthcare Biotechnology
EPIRUS Biopharmaceuticals, Inc. is in bankruptcy.

Recent & Breaking News (OTCPK:EPRSQ)

EPIRUS Biopharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

GlobeNewswire August 4, 2015

Global Markets Selling Off, 4 Stocks with Upside

Accesswire July 15, 2015

EPIRUS Biopharmaceuticals and Polpharma Group Enter Into a Multi-Product, Multi-Region, Profit-Sharing Collaboration to Advance Biosimilar Portfolio Targeting $6 Billion Addressable Innovator Market

GlobeNewswire July 14, 2015

EPIRUS Biopharmaceuticals and Polpharma Group Enter Into a Multi-Product, Multi-Region, Profit-Sharing Collaboration to Advance Biosimilar Portfolio Targeting $6 Billion Addressable Innovator Market

Thomson Reuters ONE July 14, 2015

EPIRUS Biopharmaceuticals Presents New BOW015 (Infliximab Biosimilar) Data at the European League Against Rheumatism Annual Congress (EULAR 2015)

GlobeNewswire June 10, 2015

EPIRUS Biopharmaceuticals and mAbxience Sign Latin America Distribution Deal for Infliximab Biosimilar, BOW015

GlobeNewswire May 14, 2015

EPIRUS Biopharmaceuticals Reports First Quarter 2015 Financial Results

GlobeNewswire May 12, 2015

EPIRUS Biopharmaceuticals to Present at Bank of America Merrill Lynch 2015 Healthcare Conference

GlobeNewswire May 7, 2015

EPIRUS Biopharmaceuticals to Host Biosimilar Key Opinion Leader Meeting and Webcast on March 30

GlobeNewswire March 25, 2015

EPIRUS Reports Fourth Quarter and Fiscal Year 2014 Financial Results

GlobeNewswire March 23, 2015

LifeSci Capital Initiates Coverage of EPIRUS Biopharmaceuticals

Accesswire March 11, 2015

EPIRUS to Report Fourth Quarter and Fiscal Year 2014 Financial Results on March 24, 2015

GlobeNewswire March 11, 2015

EPIRUS Biopharmaceuticals to Present at Leerink Global Healthcare Conference

Business Wire February 5, 2015

EPIRUS Prices $48 Million Public Offering of Common Stock

Business Wire January 30, 2015

EPIRUS Announces Proposed Public Offering of Common Stock

Business Wire January 26, 2015

EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS) to Ring The Nasdaq Stock Market Closing Bell

GlobeNewswire January 20, 2015

EPIRUS Biopharmaceuticals Remicade® Biosimilar, Infimab(TM), Launches in India

Business Wire December 2, 2014

Data from EPIRUS' Phase 3 Study of BOW015, a biosimilar infliximab, to be Presented as a Late Breaking Poster at the American College of Rheumatology Annual Meeting

Business Wire November 17, 2014

EPIRUS Biopharmaceuticals Reports Third Quarter Results and Provides Corporate Update

Business Wire November 10, 2014

EPIRUS and Livzon Mabpharm, Inc. Enter Collaboration Agreement for China

Business Wire September 25, 2014